Aurobindo’s near-term growth driven by US/Lannett, Europe, and Pen-G, with long-term upside from biologics/biosimilars and margin-led expansion. For the full story, visit the source.
Business
Aurobindo Pharma: Strong dose of growth opportunities
Aurobindo’s near-term growth driven by US/Lannett, Europe, and Pen-G, with long-term upside from biologics/biosimilars and margin-led expansion.
BusinessLine· 2 days ago· 2 min read
This summary is sourced from BusinessLine. Read the full article at:BusinessLine